Julien Oury joined Tevard Biosciences in June 2023 as a Principal Scientist responsible for leading in vivo preclinical studies to advance the Duchenne Muscular Dystrophy pipeline. He is a neuroscientist with over 10 years of experience working with genetic models and molecular biochemistry to discover new modes of treatment for neuromuscular diseases. Supporting development of novel therapies, Julien is experienced in leveraging mass spectrometry as a screening strategy to identify unique and targetable proteins for neuromuscular diseases.
Prior to joining Tevard Biosciences, Julien was a senior research scientist at New York University School of Medicine where he was leading preclinical development of an antibody therapy that is currently being investigated in clinical trials for congenital myasthenia and other indications.
Julien holds a PhD in Molecular Biology from the University of Strasbourg in France. During his postdoctoral fellowship at NYU School of Medicine, he served as a contributing investigator at the National Institute of Neurological Disorders and Stroke (NINDS) that focuses on translational research for patients with childhood neuromuscular disorders. He has published his work in Nature and Journal of Cell Biology among other scientific journals and has authored a chapter reviewing mechanisms in neuromuscular biology in Cold Spring Harbor Perspectives in Biology.